Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Byetta, Bydureon
Exenatide is an incretin mimetic, a glucagon-like peptide-1 (GLP-1) receptor agonist, used in the treatment of type 2 diabetes mellitus. It enhances glucose-dependent insulin secretion, suppresses inappropriately elevated glucagon secretion, slows gastric emptying, and may reduce food intake.
For improving glycemic control in adults with type 2 diabetes mellitus.
Exenatide has been associated with acute pancreatitis. Monitor patients for signs and symptoms of pancreatitis. If pancreatitis is suspected, discontinue exenatide and evaluate appropriately. Do not resume use if pancreatitis is confirmed.
Outcome:
Increased risk of bleeding
Mechanism:
Possible alteration of warfarin absorption
Outcome:
Additive effects on blood glucose lowering
Mechanism:
Independent mechanisms of action
Outcome:
Minimally delayed absorption
Mechanism:
Delayed gastric emptying
Most likely new formulation: Extended-release oral formulation (2025, 70% confidence)
Based on current usage trends and clinical trial data, there is a low likelihood of regulatory changes impacting exenatide's availability in the next 2 years.
Antidiabetic, Incretin Mimetic
Peptide